FASN and B-cell chronic lymphocytic leukemia: Moreover, Acalabrutinib treatment is associated with inhibition of fatty acid metabolism induced by fatty acid synthase (FASN) downregulation, which may trigger significant apoptosis of MCL [17] or CLL cells [14].